melatonin has been researched along with Huntington Disease in 24 studies
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we examined diurnal rhythmicity in different stages of Huntington (HD) disease and in patients with acute moderate ischemic stroke (AIS) outside the retinohypothalamic pathway by evaluating serum concentrations of melatonin and cortisol at twelve timepoints." | 7.85 | Circadian rhythms of melatonin and cortisol in manifest Huntington's disease and in acute cortical ischemic stroke. ( Adamczak-Ratajczak, A; Checinska-Maciejewska, Z; Gibas-Dorna, M; Krauss, H; Kupsz, J; Michalak, S; Owecki, M; Sowinska, A; Zielonka, D, 2017) |
| "Neurodegenerative diseases are the second most common cause of death and characterized by progressive impairments in movement or mental functioning in the central or peripheral nervous system." | 6.66 | Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases. ( Chen, D; Lee, TH; Zhang, T, 2020) |
| "Melatonin is a neuroendocrine hormone mainly synthesized in the pineal gland and exhibits a wide range of biological functions, such as sleep control, regulating circadian rhythm, immune enhancement, metabolism regulation, antioxidant, anti-aging, and anti-tumor effects." | 6.66 | Melatonin and Autophagy in Aging-Related Neurodegenerative Diseases. ( Akbar, M; Luo, F; Rungratanawanich, W; Sandhu, AF; Song, BJ; Wang, X; Williams, GE; Zhou, S, 2020) |
| "On the other hand, cerebral ischemia is a major cause of human disability all over the world." | 6.50 | The role of melatonin in multiple sclerosis, Huntington's disease and cerebral ischemia. ( Colín-González, AL; Escribano, BM; Santamaría, A; Túnez, I, 2014) |
| "Melatonin has been shown to be effective in arresting neurodegenerative phenomena seen in experimental models of Alzheimer's disease, Parkinsonism and ischemic stroke." | 6.43 | Role of melatonin in neurodegenerative diseases. ( Cardinali, DP; Esquifino, AI; Hardeland, R; Maestroni, GJ; Pandi-Perumal, SR; Srinivasan, V, 2005) |
| "Melatonin is a pleiotrophic hormone, synthesised primarily by the pineal gland under the control of the suprachiasmatic nuclei (SCN)." | 5.56 | Increased plasma melatonin in presymptomatic Huntington disease sheep (Ovis aries): Compensatory neuroprotection in a neurodegenerative disease? ( Bawden, CS; Kuchel, TR; Middleton, B; Morton, AJ; Rudiger, S; Skene, DJ, 2020) |
| "We found that Huntington's disease mice had increased mtDNA release, cGAS activation, and inflammation, all inhibited by exogenous melatonin." | 5.56 | Melatonin inhibits cytosolic mitochondrial DNA-induced neuroinflammatory signaling in accelerated aging and neurodegeneration. ( Baranov, SV; Carlisle, DL; Friedlander, RM; Jauhari, A; Kim, J; Li, F; Minnigh, MB; Oberly, P; Poloyac, SM; Singh, T; Suofu, Y; Wang, X; Yablonska, S, 2020) |
| " In this study, we examined diurnal rhythmicity in different stages of Huntington (HD) disease and in patients with acute moderate ischemic stroke (AIS) outside the retinohypothalamic pathway by evaluating serum concentrations of melatonin and cortisol at twelve timepoints." | 3.85 | Circadian rhythms of melatonin and cortisol in manifest Huntington's disease and in acute cortical ischemic stroke. ( Adamczak-Ratajczak, A; Checinska-Maciejewska, Z; Gibas-Dorna, M; Krauss, H; Kupsz, J; Michalak, S; Owecki, M; Sowinska, A; Zielonka, D, 2017) |
| "Neurodegenerative diseases are the second most common cause of death and characterized by progressive impairments in movement or mental functioning in the central or peripheral nervous system." | 2.66 | Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases. ( Chen, D; Lee, TH; Zhang, T, 2020) |
| "Melatonin is a neuroendocrine hormone mainly synthesized in the pineal gland and exhibits a wide range of biological functions, such as sleep control, regulating circadian rhythm, immune enhancement, metabolism regulation, antioxidant, anti-aging, and anti-tumor effects." | 2.66 | Melatonin and Autophagy in Aging-Related Neurodegenerative Diseases. ( Akbar, M; Luo, F; Rungratanawanich, W; Sandhu, AF; Song, BJ; Wang, X; Williams, GE; Zhou, S, 2020) |
| "In amyotrophic lateral sclerosis and Huntington's disease, WNT/beta-catenin pathway is upregulated, whereas PPAR gamma is downregulated." | 2.58 | Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms. ( Guillevin, R; Lecarpentier, Y; Vallée, A; Vallée, JN, 2018) |
| "On the other hand, cerebral ischemia is a major cause of human disability all over the world." | 2.50 | The role of melatonin in multiple sclerosis, Huntington's disease and cerebral ischemia. ( Colín-González, AL; Escribano, BM; Santamaría, A; Túnez, I, 2014) |
| "Melatonin has been shown to be effective in arresting neurodegenerative phenomena seen in experimental models of Alzheimer's disease, Parkinsonism and ischemic stroke." | 2.43 | Role of melatonin in neurodegenerative diseases. ( Cardinali, DP; Esquifino, AI; Hardeland, R; Maestroni, GJ; Pandi-Perumal, SR; Srinivasan, V, 2005) |
| "Melatonin has been shown to be highly effective in reducing oxidative damage in the central nervous system; this efficacy derives from its ability to directly scavenge a number of free radicals and to function as an indirect antioxidant." | 2.40 | Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism. ( Cabrera, J; Manchester, LC; Mayo, JC; Reiter, RJ; Sainz, RM; Tan, DX, 1999) |
| "Melatonin is a potent antioxidant and exogenous melatonin treatment is neuroprotective in experimental HD models." | 1.91 | Biosynthesis of neuroprotective melatonin is dysregulated in Huntington's disease. ( Baranov, SV; Baranova, OV; Carlisle, DL; Friedlander, RM; Heath, BE; Jia, J; Kim, J; Lariviere, WR; Larkin, TM; Li, W; Suofu, Y; Wang, J; Wang, X, 2023) |
| "Melatonin is a pleiotrophic hormone, synthesised primarily by the pineal gland under the control of the suprachiasmatic nuclei (SCN)." | 1.56 | Increased plasma melatonin in presymptomatic Huntington disease sheep (Ovis aries): Compensatory neuroprotection in a neurodegenerative disease? ( Bawden, CS; Kuchel, TR; Middleton, B; Morton, AJ; Rudiger, S; Skene, DJ, 2020) |
| "We found that Huntington's disease mice had increased mtDNA release, cGAS activation, and inflammation, all inhibited by exogenous melatonin." | 1.56 | Melatonin inhibits cytosolic mitochondrial DNA-induced neuroinflammatory signaling in accelerated aging and neurodegeneration. ( Baranov, SV; Carlisle, DL; Friedlander, RM; Jauhari, A; Kim, J; Li, F; Minnigh, MB; Oberly, P; Poloyac, SM; Singh, T; Suofu, Y; Wang, X; Yablonska, S, 2020) |
| "Melatonin concentrations are reduced in Huntington's disease." | 1.40 | Plasma melatonin is reduced in Huntington's disease. ( Björkqvist, M; Doshi, A; Frost, C; Hill, NR; Hindmarsh, P; Kalliolia, E; Nambron, R; Silajdžić, E; Warner, TT; Watt, H, 2014) |
| "Melatonin was partially effective against the inhibition of striatal catalase activity and a decrease of non-protein thiol levels induced by quinolinic acid." | 1.39 | Correlations between behavioural and oxidative parameters in a rat quinolinic acid model of Huntington's disease: protective effect of melatonin. ( Antunes Wilhelm, E; Folharini Bortolatto, C; Ricardo Jesse, C; Wayne Nogueira, C, 2013) |
| "As melatonin has a major role in the regulation of sleep and other cyclical bodily activities and its synthesis is directly regulated by the SCN, we postulated that disturbed SCN function is likely to give rise to abnormal melatonin secretion in HD." | 1.35 | Delayed onset of the diurnal melatonin rise in patients with Huntington's disease. ( Aziz, NA; Frölich, M; Pijl, H; Roelfsema, F; Roos, RA; Schröder-van der Elst, JP; van der Bent, C, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.17) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 9 (37.50) | 24.3611 |
| 2020's | 6 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, J | 2 |
| Li, W | 2 |
| Wang, J | 1 |
| Baranov, SV | 2 |
| Heath, BE | 1 |
| Jia, J | 1 |
| Suofu, Y | 2 |
| Baranova, OV | 1 |
| Wang, X | 4 |
| Larkin, TM | 1 |
| Lariviere, WR | 1 |
| Carlisle, DL | 2 |
| Friedlander, RM | 3 |
| Morton, AJ | 1 |
| Middleton, B | 1 |
| Rudiger, S | 1 |
| Bawden, CS | 1 |
| Kuchel, TR | 1 |
| Skene, DJ | 1 |
| Jauhari, A | 1 |
| Singh, T | 1 |
| Yablonska, S | 1 |
| Li, F | 1 |
| Oberly, P | 1 |
| Minnigh, MB | 1 |
| Poloyac, SM | 1 |
| Chen, D | 1 |
| Zhang, T | 1 |
| Lee, TH | 1 |
| Luo, F | 1 |
| Sandhu, AF | 1 |
| Rungratanawanich, W | 1 |
| Williams, GE | 1 |
| Akbar, M | 1 |
| Zhou, S | 2 |
| Song, BJ | 1 |
| Malik, I | 1 |
| Agrawal, N | 1 |
| Kumar, V | 1 |
| Adamczak-Ratajczak, A | 1 |
| Kupsz, J | 1 |
| Owecki, M | 1 |
| Zielonka, D | 1 |
| Sowinska, A | 1 |
| Checinska-Maciejewska, Z | 1 |
| Krauss, H | 1 |
| Michalak, S | 1 |
| Gibas-Dorna, M | 1 |
| Vallée, A | 1 |
| Lecarpentier, Y | 1 |
| Guillevin, R | 1 |
| Vallée, JN | 1 |
| Chakraborty, J | 1 |
| Nthenge-Ngumbau, DN | 1 |
| Rajamma, U | 1 |
| Mohanakumar, KP | 1 |
| Gupta, S | 1 |
| Sharma, B | 1 |
| Escribano, BM | 1 |
| Colín-González, AL | 1 |
| Santamaría, A | 1 |
| Túnez, I | 2 |
| Kalliolia, E | 1 |
| Silajdžić, E | 1 |
| Nambron, R | 1 |
| Hill, NR | 1 |
| Doshi, A | 1 |
| Frost, C | 1 |
| Watt, H | 1 |
| Hindmarsh, P | 1 |
| Björkqvist, M | 1 |
| Warner, TT | 1 |
| Aziz, NA | 1 |
| Pijl, H | 1 |
| Frölich, M | 1 |
| Schröder-van der Elst, JP | 1 |
| van der Bent, C | 1 |
| Roelfsema, F | 1 |
| Roos, RA | 1 |
| Alders, J | 1 |
| Smits, M | 1 |
| Kremer, B | 1 |
| Naarding, P | 1 |
| Sirianni, A | 1 |
| Pei, Z | 1 |
| Cormier, K | 1 |
| Smith, K | 1 |
| Jiang, J | 1 |
| Wang, H | 1 |
| Zhao, R | 1 |
| Yano, H | 1 |
| Kim, JE | 1 |
| Kristal, BS | 1 |
| Ferrante, RJ | 1 |
| Cardinali, DP | 2 |
| Pagano, ES | 1 |
| Scacchi Bernasconi, PA | 1 |
| Reynoso, R | 1 |
| Scacchi, P | 1 |
| Antunes Wilhelm, E | 1 |
| Ricardo Jesse, C | 1 |
| Folharini Bortolatto, C | 1 |
| Wayne Nogueira, C | 1 |
| Montilla, P | 1 |
| Del Carmen Muñoz, M | 1 |
| Feijóo, M | 1 |
| Salcedo, M | 1 |
| Srinivasan, V | 1 |
| Pandi-Perumal, SR | 1 |
| Maestroni, GJ | 1 |
| Esquifino, AI | 1 |
| Hardeland, R | 1 |
| Christofides, J | 1 |
| Bridel, M | 1 |
| Egerton, M | 1 |
| Mackay, GM | 1 |
| Forrest, CM | 1 |
| Stoy, N | 1 |
| Darlington, LG | 1 |
| Stone, TW | 1 |
| Reiter, RJ | 1 |
| Cabrera, J | 1 |
| Sainz, RM | 1 |
| Mayo, JC | 1 |
| Manchester, LC | 1 |
| Tan, DX | 1 |
| Heiser, V | 1 |
| Scherzinger, E | 1 |
| Boeddrich, A | 1 |
| Nordhoff, E | 1 |
| Lurz, R | 1 |
| Schugardt, N | 1 |
| Lehrach, H | 1 |
| Wanker, EE | 1 |
| Burton, S | 1 |
| Daya, S | 1 |
| Potgieter, B | 1 |
| Jones, RL | 1 |
| McGeer, PL | 1 |
| Greiner, AC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease[NCT04287543] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2021-05-31 | Withdrawn (stopped due to Due to the COVID-19 pandemic, we were unable to begin the study) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for melatonin and Huntington Disease
| Article | Year |
|---|---|
Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Circadian Rhythm; Dementia, Vascular; Hum | 2020 |
Melatonin and Autophagy in Aging-Related Neurodegenerative Diseases.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Antioxidants; Autophagy; Autophagy | 2020 |
Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms.
Topics: Adenosine Triphosphate; Aerobiosis; Amyotrophic Lateral Sclerosis; Brain; Circadian Rhythm; Energy M | 2018 |
The role of melatonin in multiple sclerosis, Huntington's disease and cerebral ischemia.
Topics: Brain Ischemia; Disease Progression; Humans; Huntington Disease; Melatonin; Multiple Sclerosis | 2014 |
Melatonin and mitochondrial dysfunction in the central nervous system.
Topics: Alzheimer Disease; Animals; Humans; Huntington Disease; Melatonin; Mitochondria; Parkinson Disease | 2013 |
Role of melatonin in neurodegenerative diseases.
Topics: Aging; Alzheimer Disease; Animals; Antioxidants; Brain Chemistry; Brain Injuries; Free Radical Scave | 2005 |
Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism.
Topics: Alzheimer Disease; Animals; Cell Death; Drug Evaluation, Preclinical; Free Radical Scavengers; Free | 1999 |
17 other studies available for melatonin and Huntington Disease
| Article | Year |
|---|---|
Biosynthesis of neuroprotective melatonin is dysregulated in Huntington's disease.
Topics: Animals; Humans; Huntington Disease; Melatonin; Mice; Pineal Gland | 2023 |
Increased plasma melatonin in presymptomatic Huntington disease sheep (Ovis aries): Compensatory neuroprotection in a neurodegenerative disease?
Topics: Animals; Circadian Rhythm; Disease Models, Animal; Female; Humans; Huntington Disease; Male; Melaton | 2020 |
Melatonin inhibits cytosolic mitochondrial DNA-induced neuroinflammatory signaling in accelerated aging and neurodegeneration.
Topics: Aging; Animals; Cytosol; DNA, Mitochondrial; Female; Humans; Huntington Disease; Male; Melatonin; Mi | 2020 |
Melatonin and curcumin reestablish disturbed circadian gene expressions and restore locomotion ability and eclosion behavior in
Topics: Animals; Circadian Rhythm; Curcumin; Drosophila; Drosophila Proteins; Gene Expression; Humans; Hunti | 2021 |
Circadian rhythms of melatonin and cortisol in manifest Huntington's disease and in acute cortical ischemic stroke.
Topics: Brain Ischemia; Circadian Rhythm; Humans; Huntington Disease; Hydrocortisone; Male; Melatonin; Middl | 2017 |
Melatonin protects against behavioural dysfunctions and dendritic spine damage in 3-nitropropionic acid-induced rat model of Huntington's disease.
Topics: Animals; Convulsants; Dendritic Spines; Disease Models, Animal; Dose-Response Relationship, Drug; Dr | 2014 |
Pharmacological benefits of agomelatine and vanillin in experimental model of Huntington's disease.
Topics: Acetamides; Animals; Benzaldehydes; Disease Models, Animal; Female; Huntington Disease; Male; Maze L | 2014 |
Plasma melatonin is reduced in Huntington's disease.
Topics: Adult; Aged; Female; Fourier Analysis; Humans; Huntington Disease; Male; Melatonin; Middle Aged; Sev | 2014 |
Delayed onset of the diurnal melatonin rise in patients with Huntington's disease.
Topics: Chronobiology Disorders; Circadian Rhythm; Disease Progression; Down-Regulation; Female; Humans; Hun | 2009 |
The role of melatonin in sleep disturbances in end-stage Huntington's disease.
Topics: Humans; Huntington Disease; Melatonin; Sleep Wake Disorders; Time Factors | 2009 |
The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity.
Topics: Analysis of Variance; Animals; Brain; Caspase 3; Caspase 9; Cell Death; Cells, Cultured; Disease Mod | 2011 |
Correlations between behavioural and oxidative parameters in a rat quinolinic acid model of Huntington's disease: protective effect of melatonin.
Topics: Animals; Behavior, Animal; Catalase; Disease Models, Animal; Huntington Disease; Male; Melatonin; Mo | 2013 |
Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease.
Topics: Animals; Antioxidants; Brain; Disease Models, Animal; Huntington Disease; Lipid Peroxidation; Male; | 2004 |
Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington's disease or chronic brain injury.
Topics: Administration, Oral; Aged; Biomarkers; Brain; Brain Injury, Chronic; Down-Regulation; Female; Food, | 2006 |
Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy.
Topics: Animals; Antibodies, Monoclonal; Benzoates; Benzothiazoles; Biphenyl Compounds; Congo Red; COS Cells | 2000 |
Melatonin modulates apomorphine-induced rotational behaviour.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Hun | 1991 |
Metabolism of exogenous melatonin in schizophrenic and non-schizophrenic volunteers.
Topics: Animals; Autoradiography; Brain Damage, Chronic; Carbon Isotopes; Chromatography, Gel; Chromatograph | 1969 |